EU Commission to restrict Chinese companies in medical devices procurement
The European Commission, the primary executive arm of the EU, announced their decision to exclude Chinese companies from EU government purchases of medical devices exceeding EUR€5 million in a bid to rebalance trade barriers.
The decision follows results from an initial investigation under the International Procurement Instrument (IPI), and will allow no more than 50% of inputs from China for successful procurement bids, though exclusions apply if no alternative suppliers are available. The IPI investigation and subsequent decision are in response to what the Commission deems proportionate to barriers in China, aiming to incentivise China to include EU-made medical devices in Chinese government contracts.
From 2015 to 2023, imports of Chinese medical devices to the EU more than doubled, while China has made it significantly more difficult for EU companies to export to their market – 87% of public procurement contracts for medical devices in China were subject to legislation the EU Commission claims are “exclusionary and discriminatory”. EU officials also claim Medtech Europe figures value the EU medical technology market at approximately EUR€150 billion in 2023, with public procurement making up 70%. With global public procurement valued at over EUR€11 trillion annually, the EU public procurement market states it is one of the most open markets globally. The EU Commission’s ban would cover medical devices such as imaging equipment, artificial body parts, and medical clothing. The Commission also stated that “clear evidence” showed China favouring Chinese devices for hospitals, and that its tender conditions continually resulted in low bids.
While dialogue between the two regions is still open, China’s commerce ministry has previously called the measures as “protectionist”, and urged for transparency on both sides to resolve the issues. Meanwhile, the EU Commission has stated that China has not proposed any concrete and satisfactory solutions, leading to the implementation of such measures.
Sources:
Commission restricts Chinese participation in medical devices procurement [Accessed June 23, 2025] https://ec.europa.eu/commission/presscorner/detail/en/ip_25_1569
EU bars Chinese firms from most medical device tenders [Accessed June 23, 2025] https://www.reuters.com./business/healthcare-pharmaceuticals/eu-bars-chinese-firms-most-medical-device-tenders-2025-06-20/
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...